These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. Rascol O Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197 [TBL] [Abstract][Full Text] [Related]
7. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States. Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691 [TBL] [Abstract][Full Text] [Related]
8. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Stocchi F; Marconi S Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107 [TBL] [Abstract][Full Text] [Related]
10. Duodenal levodopa infusion for the treatment of Parkinson's disease. Samanta J; Hauser RA Expert Opin Pharmacother; 2007 Apr; 8(5):657-64. PubMed ID: 17376020 [TBL] [Abstract][Full Text] [Related]
11. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study. Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069 [TBL] [Abstract][Full Text] [Related]
12. Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients. Raudino F; Garavaglia P; Pianezzola C; Riboldazzi G; Leva S; Guidotti M; Bono G Neurol Sci; 2009 Feb; 30(1):85-6. PubMed ID: 19169622 [No Abstract] [Full Text] [Related]
14. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. Abbruzzese G; Barone P; Bonuccelli U; Lopiano L; Antonini A Funct Neurol; 2012; 27(3):147-54. PubMed ID: 23402675 [TBL] [Abstract][Full Text] [Related]
15. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Olanow CW; Obeso JA; Stocchi F Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589 [TBL] [Abstract][Full Text] [Related]
16. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital]. Santos-García D; Macías M; Llaneza M; Fuster-Sanjurjo L; Echarri-Piudo A; Belmonte S; Blanco S Neurologia; 2010; 25(9):536-43. PubMed ID: 21093702 [TBL] [Abstract][Full Text] [Related]
17. Myths and realities of continuous dopaminergic stimulation. Pirtošek Z Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. Nyholm D Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914 [TBL] [Abstract][Full Text] [Related]